Who’s pumping GW Pharmaceuticals? Anyone?
Don’t know, don’t care. It’s another 13.5% tacked on to a previous profitable seasonal bottom feed trade. It’s a market that is re-developing its high risk profile and profit taking is part of risk management. I’ve already sold two newsletter pumps in the last week and I can’t find a publicly available reason for this. So… thank you sir.
That said, it is technically aiming for the a gap fill and test of the down-sloped SMA 200. But profit be profit.
Subscribe to NFTRH Premium (monthly at USD $35.00 or a discounted yearly at USD $365.00) for an in-depth weekly market report, interim market updates and NFTRH+ chart and trade setup ideas. You can also keep up to date with actionable public content at NFTRH.com by using the email form on the right sidebar and get even more by joining our free eLetter. Follow via Twitter @NFTRHgt or StockTwits.